

Victor A Levin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10842218/publications.pdf>

Version: 2024-02-01

154
papers

12,689
citations

25034

57
h-index

23533

111
g-index

156
all docs

156
docs citations

156
times ranked

7732
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory. <i>Neurotherapeutics</i> , 2022, 19, 1855-1868.	4.4	1
2	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa124.	0.7	5
3	Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells. <i>Oncotarget</i> , 2020, 11, 3933-3942.	1.8	1
4	How far will the Voyager® take us?. <i>CNS Oncology</i> , 2019, 8, CNS26.	3.0	1
5	Understanding brain penetrance of anticancer drugs. <i>Neuro-Oncology</i> , 2018, 20, 589-596.	1.2	12
6	Clinical importance of eflornithine (±-difluoromethylornithine) for the treatment of malignant gliomas. <i>CNS Oncology</i> , 2018, 7, CNS16.	3.0	27
7	Drug discovery in neuro-oncology: challenges in the path forward. <i>Neuro-Oncology</i> , 2018, 20, 435-436.	1.2	3
8	Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. <i>Journal of Neuro-Oncology</i> , 2018, 136, 79-86.	2.9	21
9	Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab. <i>Journal of Neuro-Oncology</i> , 2017, 134, 325-330.	2.9	41
10	CNS Anticancer Drug Discovery and Development: 2016 conference insights. <i>CNS Oncology</i> , 2017, 6, 167-177.	3.0	10
11	Personalized medicine in neuro-oncology. <i>CNS Oncology</i> , 2016, 5, 55-58.	3.0	8
12	Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 122, 145-150.	2.9	52
13	Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 266-273.	1.2	61
14	Getting More Out of Survival Data by Using the Hazard Function. <i>Clinical Cancer Research</i> , 2014, 20, 1404-1409.	7.0	48
15	Treatment of anaplastic oligodendrogliomas: should resources be used to codify the old or to create the new?. <i>Oncology</i> , 2013, 27, 322, 324.	0.5	0
16	Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. <i>Neuro-Oncology</i> , 2012, 14, 1511-1518.	1.2	95
17	Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. <i>Cancer</i> , 2012, 118, 3599-3606.	4.1	13
18	Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures. <i>Proteome Science</i> , 2012, 10, 5.	1.7	21

#	ARTICLE	IF	CITATIONS
19	A systematic approach to the management of patients with brain metastases of known or unknown primary site. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1-13.	2.3	31
20	Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience. <i>Blood</i> , 2012, 120, 3670-3670.	1.4	7
21	Modulation of Glioma Risk and Progression by Dietary Nutrients and Antiinflammatory Agents. <i>Nutrition and Cancer</i> , 2011, 63, 174-184.	2.0	49
22	An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 971-983.	2.3	31
23	Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2011, 102, 273-280.	2.9	26
24	Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1487-1495.	0.8	611
25	Different Changes in Protein and Phosphoprotein Levels Result from Serum Starvation of High-Grade Glioma and Adenocarcinoma Cell Lines. <i>Journal of Proteome Research</i> , 2010, 9, 179-191.	3.7	66
26	Role of bevacizumab therapy in the management of glioblastoma. <i>Cancer Management and Research</i> , 2010, 2, 97-104.	1.9	16
27	Melding a New 3-Dimensional Agarose Colony Assay with the Emax Model to Determine the Effects of Drug Combinations on Cancer Cells. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 163-175.	1.9	4
28	Chemotherapy as first line treatment for oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2008, 86, 361-362.	2.9	0
29	In Reply to Dr. Healy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 629-630.	0.8	0
30	Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 733-741.	2.4	8
31	Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2008, 10, 216-222.	1.2	52
32	Long-term Anti-inflammatory and Antihistamine Medication Use and Adult Glioma Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1277-1281.	2.5	79
33	A New Preclinical 3-Dimensional Agarose Colony Formation Assay. <i>Technology in Cancer Research and Treatment</i> , 2008, 7, 329-334.	1.9	14
34	NEUROIMAGING IN NEURO-ONCOLOGY. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2008, 14, 77-93.	0.8	0
35	Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO+PCV chemotherapy. <i>International Journal of Cancer</i> , 2007, 121, 2279-2283.	5.1	12
36	Effect of bevacizumab on radiation necrosis of the brain. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 323-326.	0.8	383

#	ARTICLE	IF	CITATIONS
37	Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. <i>BMC Cancer</i> , 2007, 7, 106.	2.6	14
38	Are Gliomas Preventable?. , 2007, 174, 205-215.		10
39	Lysate array analyses of signal transduction inhibitors in tumor cell lines. <i>Clinical Proteomics</i> , 2006, 2, 33-43.	2.1	2
40	Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation~.... <i>Journal of Neuro-Oncology</i> , 2006, 78, 295-302.	2.9	111
41	Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status. <i>Journal of Neuro-Oncology</i> , 2006, 80, 83-90.	2.9	53
42	Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 4282-4289.	1.6	79
43	13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2004, 6, 253-258.	1.2	61
44	Tissue-based Assay for Ornithine Decarboxylase to Identify Patients Likely to Respond to Difluoromethylornithine. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 1467-1474.	2.5	8
45	Basis and Importance of SRC as a Target in Cancer. , 2004, 119, 89-119.		36
46	Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015. <i>Journal of Neuro-Oncology</i> , 2003, 62, 251-258.	2.9	10
47	Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 519-528.	0.8	62
48	Stereotactic Injection of DTI-015 into Recurrent Malignant Gliomas: Phase I/II Trial. <i>Neoplasia</i> , 2003, 5, 9-16.	5.3	36
49	Anaplastic Oligodendrogliomas: Prognostic Factors for Tumor Recurrence and Survival. <i>Oncology</i> , 2003, 65, 259-266.	1.9	72
50	Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. <i>Clinical Cancer Research</i> , 2003, 9, 981-90.	7.0	92
51	Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies. <i>Neuro-Oncology</i> , 2002, 4, 268-277.	1.2	41
52	Phase II Trial of Temozolomide Plus the Matrix Metalloproteinase Inhibitor, Marimastat, in Recurrent and Progressive Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2002, 20, 1383-1388.	1.6	184
53	Risk assessment for developing gliomas: a comparison of two cytogenetic approaches. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2001, 490, 35-44.	1.7	13
54	Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors. <i>Neuro-Oncology</i> , 2001, 3, 241-245.	1.2	11

#	ARTICLE	IF	CITATIONS
55	Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2000, 18, 708-708.	1.6	413
56	Cognitive Function as a Predictor of Survival in Patients With Recurrent Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2000, 18, 646-646.	1.6	246
57	Malignant Gliomas: MR Imaging Spectrum of Radiation Therapy- and Chemotherapy-induced Necrosis of the Brain after Treatment. <i>Radiology</i> , 2000, 217, 377-384.	7.3	607
58	Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: The past decade and where we are heading. <i>Neuro-Oncology</i> , 1999, 1, 69-80.	1.2	37
59	Increased chromosomal instability in peripheral lymphocytes and risk of human gliomas. <i>Carcinogenesis</i> , 1999, 20, 811-815.	2.8	16
60	A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 127-135.	0.8	47
61	Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse. <i>Journal of Clinical Oncology</i> , 1999, 17, 2762-2762.	1.6	710
62	Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 1999, 17, 2572-2572.	1.6	850
63	Response and progression in recurrent malignant glioma. <i>Neuro-Oncology</i> , 1999, 1, 282-288.	1.2	34
64	Identification of allelic loss on chromosome arm 6p in human astrocytomas by arbitrarily primed polymerase chain reaction. , 1998, 22, 165-170.		15
65	The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin). <i>Journal of Neuro-Oncology</i> , 1997, 34, 145-151.	2.9	50
66	Tight-binding inhibitory sequences against pp60câˆ’rc identified using a random 15-amino-acid peptide library. <i>FEBS Letters</i> , 1996, 399, 237-240.	2.8	41
67	Combination of 6-Thioguanine, Procarbazine, Lomustine, and Hydroxyurea for Patients with Recurrent Malignant Gliomas. <i>Neurosurgery</i> , 1996, 39, 921-926.	1.1	23
68	Controversies in the treatment of low-grade astrocytomas and oligodendrogliomas. <i>Current Opinion in Oncology</i> , 1996, 8, 175-177.	2.4	16
69	Correlation of p53 immunoreactivity and sequencing in patients with glioma. <i>Molecular Carcinogenesis</i> , 1996, 15, 1-4.	2.7	28
70	Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. <i>Journal of Neuro-Oncology</i> , 1996, 30, 61-9.	2.9	159
71	Correlation of p53 immunoreactivity and sequencing in patients with glioma. <i>Molecular Carcinogenesis</i> , 1996, 15, 1-4.	2.7	1
72	Combination of 6-Thioguanine, Procarbazine, Lomustine, and Hydroxyurea for Patients with Recurrent Malignant Gliomas. <i>Neurosurgery</i> , 1996, 39, 921-926.	1.1	19

#	ARTICLE	IF	CITATIONS
73	The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. <i>Cancer</i> , 1995, 75, 1151-1161.	4.1	425
74	Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 75-83.	0.8	75
75	The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 85-91.	0.8	53
76	Discovery, Development, and Testing of Substrates and Inhibitors of pp60C-SRC. <i>International Journal of Pharmacognosy</i> , 1995, 33, 27-34.	0.2	2
77	Pattern of recurrence of medulloblastoma after low-dose. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 30, 551-556.	0.8	46
78	Prognostic Significance of Bromodeoxyuridine Labeling in Primary and Recurrent Glioblastoma Multiforme. <i>Neurosurgery</i> , 1994, 35, 192-198.	1.1	21
79	Prognostic Significance of Bromodeoxyuridine Labeling in Primary and Recurrent Glioblastoma Multiforme. <i>Neurosurgery</i> , 1994, 35, 192-198.	1.1	1
80	Lipid peroxidation does not appear to be a factor in late radiation injury of the cervical spinal cord of rats. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 25, 67-72.	0.8	5
81	Bacterial expression of an active tyrosine kinase from a protein A/truncated c-src fusion protein. <i>FEBS Letters</i> , 1993, 327, 224-230.	2.8	11
82	Imaging patterns of multifocal gliomas. <i>European Journal of Radiology</i> , 1993, 16, 163-170.	2.6	88
83	The Treatment of Anaplastic Oligodendrogliomas and Mixed Gliomas. <i>Neurosurgery</i> , 1993, 32, 365-371.	1.1	97
84	The Treatment of Anaplastic Oligodendrogliomas and Mixed Gliomas. <i>Neurosurgery</i> , 1993, 32, 365-371.	1.1	7
85	Primary central nervous system lymphoma: a role for adjuvant chemotherapy. <i>Journal of Neuro-Oncology</i> , 1992, 14, 271-5.	2.9	56
86	Hyperfractionated radiation therapy for gliomas of the brainstem in children and in adults. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 24, 599-610.	0.8	66
87	Alternative splicing of neurofibromatosis type 1 gene transcript in malignant brain tumors: PCR analysis of frozen-section mRNA. <i>Molecular Carcinogenesis</i> , 1992, 6, 83-87.	2.7	19
88	External irradiation followed by an interstitial high activity iodine-125 implant boost in the initial treatment of malignant gliomas: NCOG study 6G-82-2 gliomas: NCOG study 6H-82-2. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991, 21, 601-606.	0.8	198
89	Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. <i>Journal of Neurosurgery</i> , 1991, 74, 701-708.	1.6	166
90	Management of Hypothalamic Gliomas in Children: An Analysis of 33 Cases. <i>Neurosurgery</i> , 1990, 26, 242-247.	1.1	102

#	ARTICLE	IF	CITATIONS
91	Poorly differentiated gliomas of the cerebellum. A study of 18 patients. <i>Cancer</i> , 1990, 65, 337-340.	4.1	40
92	Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. <i>International Journal of Radiation Oncology Biology Physics</i> , 1990, 18, 321-324.	0.8	385
93	Hyperfractionated radiation therapy for brain-stem glioma: a Phase II trial. <i>Journal of Neurosurgery</i> , 1989, 70, 691-700.	1.6	116
94	Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. <i>Cancer</i> , 1989, 64, 2420-2423.	4.1	76
95	Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, 301-307.	2.3	29
96	A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors. <i>Journal of Neuro-Oncology</i> , 1988, 6, 319-23.	2.9	20
97	Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine. <i>Journal of Neurosurgery</i> , 1988, 68, 383-387.	1.6	52
98	PET of malignant cerebral tumors after interstitial brachytherapy. <i>Journal of Neurosurgery</i> , 1988, 69, 830-838.	1.6	186
99	Prognostic implications of the proliferative potential of low-grade astrocytomas. <i>Journal of Neurosurgery</i> , 1988, 69, 839-842.	1.6	150
100	A Phase II Trial of Oral Melphalan in Recurrent Primary Brain Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1988, 11, 52-54.	1.3	15
101	Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. <i>Journal of Neurosurgery</i> , 1987, 67, 864-873.	1.6	203
102	Differentiation of Cerebral Radiation Necrosis from Tumor Recurrence by [¹⁸ F]FDG and ⁸² Rb Positron Emission Tomography. <i>Journal of Computer Assisted Tomography</i> , 1987, 11, 563-570.	0.9	157
103	Reoperation for Recurrent Glioblastoma and Anaplastic Astrocytoma. <i>Neurosurgery</i> , 1987, 21, 615-621.	1.1	247
104	Clinical anticancer pharmacology: Some pharmacokinetic considerations. <i>Cancer Treatment Reviews</i> , 1986, 13, 61-76.	7.7	18
105	Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. <i>Journal of Neurosurgery</i> , 1986, 65, 654-658.	1.6	225
106	Retreatment of pediatric brain tumors with radiation and misonidazole: Results of a CCSSG/RTOG phase I/II study. <i>Cancer</i> , 1986, 58, 1636-1640.	4.1	21
107	In Vitro Cytotoxic Effects of Dibromodulcitol in 9L Rat Brain Tumor Cells. <i>Pharmaceutical Research</i> , 1986, 03, 302-306.	3.5	2
108	Pharmacokinetic approaches to drug distribution in the cerebrospinal fluid based on ventricular administration in beagle dogs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1985, 13, 387-403.	0.6	8

#	ARTICLE	IF	CITATIONS
109	Cell kinetic studies of in situ human brain tumors with bromodeoxyuridine. <i>Cytometry</i> , 1985, 6, 627-632.	1.8	160
110	Chemotherapy of Primary Brain Tumors. <i>Neurologic Clinics</i> , 1985, 3, 855-866.	1.8	76
111	Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. <i>Journal of Neurosurgery</i> , 1985, 63, 218-223.	1.6	108
112	Phase II evaluation of dibromodulcitol in the treatment of recurrent medulloblastoma, ependymoma, and malignant astrocytoma. <i>Journal of Neurosurgery</i> , 1984, 61, 1063-1068.	1.6	30
113	Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources. <i>Journal of Neurosurgery</i> , 1984, 60, 61-68.	1.6	183
114	Relationship of octanol/water partition coefficient and molecular weight to cellular permeability and partitioning in s49 lymphoma cells. <i>Pharmaceutical Research</i> , 1984, 01, 259-266.	3.5	19
115	CNS toxicity and CSF pharmacokinetics of intraventricular DFMO and MGBG in beagle dogs. <i>Cancer Chemotherapy and Pharmacology</i> , 1984, 13, 200-205.	2.3	7
116	5-Fluorouracil and 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) Followed by Hydroxyurea, Misonidazole, and Irradiation for Brain Stem Gliomas: A Pilot Study of the Brain Tumor Research Center and the Childrens Cancer Group. <i>Neurosurgery</i> , 1984, 14, 679-681.	1.1	77
117	Supratentorial malignant gliomas of childhood. <i>Journal of Neurosurgery</i> , 1984, 60, 495-499.	1.6	59
118	Improvement in survival produced by sequential therapies in the treatment of recurrent medulloblastoma. <i>Cancer</i> , 1983, 51, 1364-1370.	4.1	54
119	Chemotherapy of Recurrent Pediatric Posterior Fossa Tumors. <i>Neurosurgery</i> , 1983, 30, 209-225.	1.1	1
120	Clinical Correlations of Cerebrospinal Fluid Polyamine Levels. , 1983, , 441-452.		1
121	Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 8, 285-91.	2.3	73
122	Chemotherapeutic approaches to brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 8, 125-131.	2.3	18
123	Final report on the united states phase i clinical trial of the hypoxic cell radiosensitizer, misonidazole (RO-07-0582; NSC #261037). <i>Cancer</i> , 1981, 48, 1697-1704.	4.1	45
124	Csf polyamines: A new and important means of monitoring patients with medulloblastoma. <i>Cancer</i> , 1981, 47, 757-760.	4.1	73
125	Putrescine diffusion in cat brain and capillary permeability in rat brain: Relation to CSF putrescine levels in brain tumor patients. <i>European Journal of Cancer</i> , 1981, 17, 143-147.	0.9	11
126	Chemotherapy of pediatric brain-stem tumors. <i>Journal of Neurosurgery</i> , 1981, 54, 721-725.	1.6	60

#	ARTICLE	IF	CITATIONS
127	CLINICAL CHARACTERISTICS OF CANCER IN THE BRAIN AND SPINAL CORD. , 1981, , 167-197.		1
128	CLINICAL PHARMACOLOGY OF THE NITROSOUREAS. , 1981, , 171-180.		13
129	CHEMOTHERAPY OF RECURRENT BRAIN TUMORS. , 1981, , 259-268.		7
130	Heuristic modeling of drug delivery to malignant brain tumors. Journal of Pharmacokinetics and Pharmacodynamics, 1980, 8, 257-296.	0.6	98
131	Prognostic significance of the pretreatment CT scan on time to progression for patients with malignant gliomas. Journal of Neurosurgery, 1980, 52, 642-647.	1.6	54
132	Cysts in malignant gliomas. Journal of Neurosurgery, 1980, 53, 821-825.	1.6	33
133	Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. Journal of Medicinal Chemistry, 1980, 23, 682-684.	6.4	773
134	A Phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. Journal of Neurosurgery, 1979, 51, 526-532.	1.6	94
135	Evaluation of malignant glioma patients during the postirradiation period. Journal of Neurosurgery, 1979, 50, 624-628.	1.6	126
136	Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. International Journal of Radiation Oncology Biology Physics, 1979, 5, 775-786.	0.8	109
137	Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation. International Journal of Radiation Oncology Biology Physics, 1979, 5, 1573-1576.	0.8	5
138	Quantitative observations of the acute effects of X-irradiation on brain capillary permeability: Part I. International Journal of Radiation Oncology Biology Physics, 1979, 5, 1627-1631.	0.8	53
139	Quantitative observations of the subacute effects of X irradiation on brain capillary permeability: Part II. International Journal of Radiation Oncology Biology Physics, 1979, 5, 1633-1635.	0.8	18
140	Quantitative high-pressure liquid chromatographic procedure for the determination of plasma and tissue levels of 2,4-diamino-5-(3,4-dichlorophenyl)-6-methylpyrimidine (metoprine) and its application to the measurement of brain capillary permeability coefficients. Journal of Chromatography A, 1978, 156, 181-187.	3.7	4
141	Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens. Cancer Chemotherapy and Pharmacology, 1978, 1, 41-8.	2.3	16
142	The Concept of Drug Dose for in Vitro Studies with Chemotherapeutic Agents. Radiation Research, 1978, 76, 441.	1.5	31
143	Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey. Journal of Neurosurgery, 1978, 48, 587-593.	1.6	91
144	Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. Journal of Neurosurgery, 1978, 49, 589-592.	1.6	62

#	ARTICLE	IF	CITATIONS
145	Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. Journal of Neurosurgery, 1977, 47, 329-335.	1.6	180
146	Brain-tumor chemotherapy. Journal of Neurosurgery, 1977, 46, 155-164.	1.6	37
147	Computed Tomography in the Evaluation of Malignant Glioma Before and After Therapy. Radiology, 1976, 121, 85-88.	7.3	66
148	The application of brain capillary permeability coefficient measurements to pathological conditions and the selection of agents which cross the blood-brain barrier. Journal of Pharmacokinetics and Pharmacodynamics, 1976, 4, 499-519.	0.6	78
149	Nitrosoureas: Clinical and Experimental Considerations in the Treatment of Brain Tumors. , 1976, , 277-283.		0
150	Peripheral Nerve Segmental Demyelination Induced by Intraneural Diphtheria Toxin Injection. Archives of Neurology, 1974, 30, 163.	4.5	4
151	Procarbazine hydrochloride in the treatment of brain tumors. Journal of Neurosurgery, 1974, 40, 365-371.	1.6	89
152	Distribution of 5-Fluorouracil-2-14 C and Its Metabolites in a Murine Glioma2. Journal of the National Cancer Institute, 1972, 49, 1577-1584.	6.3	31
153	Blood Volume, Hematocrit and Pressure Relationships in the Isolated Perfused Dog Brain. Stroke, 1970, 1, 270-277.	2.0	6
154	Extracellular space of the cerebral cortex of normothermic and hypothermic cats. Experimental Neurology, 1970, 27, 101-114.	4.1	65